ストックスクリーナーアプリを入手
22.75
3.64%
0.80
アフターアワーズ：
22.75
前日終値:
$21.95
開ける：
$22.34
24時間の取引高:
239.75K
Relative Volume:
0.48
時価総額：
$1.01B
収益：
-
当期純損益:
$-166.31M
株価収益率:
-5.1007
EPS:
-4.4602
ネットキャッシュフロー:
$-160.59M
1週間 パフォーマンス:
-0.26%
1か月 パフォーマンス:
-2.32%
6か月 パフォーマンス:
+32.50%
1年 パフォーマンス:
+19.80%
1日の値動き範囲:
$22.34
$22.98
1週間の範囲:
$21.09
$23.20
52週間の値動き範囲:
$15.47
$27.22
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Compare AVBP vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
22.75 | 970.23M | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - Defense World
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - MyChesCo
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat
B. Riley Securities Maintains Buy on ArriVent... - Benzinga
Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm
Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart
Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - The National Law Review
ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView
ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026 - Stock Titan
Lung and ovarian cancer drug data from ArriVent to debut at 2026 AACR - Stock Titan
Stock Report: What drives Assurant Incs stock price2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP - MarketBeat
Anson Funds Management LP Makes New Investment in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (AVBP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Suvretta Capital Management LLC Buys 290,664 Shares of ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at BTIG Research - MarketBeat
Wall Street analysts see a 70.37% upside in ArriVent BioPharma, Inc. (AVBP): Can the stock really move this high? - MSN
Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research - MarketBeat
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target - TipRanks
BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline - Investing.com Canada
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year? - Bitget
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings - Sahm
Cantor Fitzgerald initiates coverage of ArriVent BioPharma (AVBP) with overweight recommendation - MSN
Whats the profit margin of ArriVent BioPharma IncWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00 - MarketBeat
Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains - simplywall.st
ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP) - MarketBeat
Oppenheimer Adjusts Price Target on ArriVent BioPharma to $50 From $44, Maintains Outperform Rating - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00 - MarketBeat
Jones Trading Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
ArriVent BioPharma Reports 2025 Financial Results and Advances Firmonertinib & ADC Pipeline with Key Phase 3 NSCLC Trials and Cash Runway Into 2027 - Minichart
EPS Watch: Whats next for ArriVent BioPharma Inc stock2025 Buyback Activity & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
ArriVent BioPharma Reports Full Year 2025 Financial Results - Bitget
ArriVent BioPharma (NASDAQ: AVBP) widens 2025 loss as R&D spend climbs - Stock Titan
ArriVent lines up mid-2026 lung cancer data, backed by $312.8M cash - Stock Titan
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):